Seema Sheoran
Stock Analyst at Rodman & Renshaw
(2.36)
# 3,020
Out of 4,509 analysts
5
Total ratings
40%
Success rate
12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Seema Sheoran
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Initiated Coverage: Buy | $70 | $38.32 | +82.67% | 1 | Jun 3, 2026 | |
| AVXL Anavex Life Sciences | Initiated Coverage: Buy | $20 | $2.35 | +751.06% | 1 | May 4, 2026 | |
| CAMP Camp4 Therapeutics | Initiated Coverage: Buy | $7 | $4.50 | +55.56% | 1 | Apr 14, 2026 | |
| SABS SAB Biotherapeutics | Initiated Coverage: Buy | $13 | $3.73 | +248.53% | 1 | Apr 2, 2026 | |
| SGMT Sagimet Biosciences | Initiated Coverage: Buy | $28 | $7.15 | +291.61% | 1 | Mar 26, 2026 |
Neurogene
Jun 3, 2026
Initiated Coverage: Buy
Price Target: $70
Current: $38.32
Upside: +82.67%
Anavex Life Sciences
May 4, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $2.35
Upside: +751.06%
Camp4 Therapeutics
Apr 14, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $4.50
Upside: +55.56%
SAB Biotherapeutics
Apr 2, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $3.73
Upside: +248.53%
Sagimet Biosciences
Mar 26, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $7.15
Upside: +291.61%